Inclusion Criteria:~* Subject has completed the Week 78 of the Phase 3 core study (ALZ-801-AD301) while on
study drug.~* Subject has a reliable study partner who has sufficient contact with the subject to be able to
provide accurate information about the subject's cognitive and functional abilities.~
